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The Ancient Greeks are often credited as the first to acknowledge the challenges of perianal 
sepsis and associated fistulae [1]. Indeed 2500 years of enquiry have seen numerous 
procedures offered to patients, many burdened by their own inherent problems and none 
widely considered to represent optimal treatment. Modern-day anal fistula management can 
be complex and require a multidisciplinary input in Crohn’s disease. The addition of 
radiological assessment to thorough clinical examination facilitates anatomical delineation, 
usually using Parks’ classification. The most difficult fistulae are often those too high to be 
amenable to laying open, which has the best chance of healing. Whilst rarely a life-
threatening condition, the disappointment of recurrent failure is difficult for patients, who may 
have to consider treatments which can impair sphincter function. One problem is the 
contentious issue of defining treatment success and/or fistula healing which are often 
synonymous.  
The Societa Italiana di Chirurgia ColoRettale (SICCR) recently published a position 
statement on perianal fistulae [2]. Amongst a variety of issues, they specifically addressed 
the use of Fistula Laser Closing (FiLaC) to ablate the fistulous tract, with or without internal 
opening closure, in ‘complex fistulae’. The 2C recommendation was based on literature prior 
to the recently published study by Wilhelm and colleagues in this journal [3], but they 
nevertheless highlighted the low morbidity and potential of this procedure and that it 
warranted further investigation. A separate expert group from the UK looked specifically at 
perianal fistulae in Crohn’s disease [4]. They sought to address a number of areas in 
perianal Crohn’s disease, and included details of surgical carein their questionnaire were . 
Unfortunately, only 0.6% of surgeons across 32 centres cited experience of FiLaC reflecting 
limited uptake at present. 
In this journal, Wilhelm and colleagues have reported on their long-term follow- up data 
using FiLAC in patients with diagnosed high fistulae [3]. FiLaC uses a radial emitting diode 
laser to obliterate the fistula with or without closing the internal opening. This study, currently 
the largest series, included 117 patients over a period of just under 5 years who had 
undergone clinical and radiological examination with endoanal ultrasound ( EAUS). Both 
surgery and EAUS were performed by a single surgeon. The primary outcome measure was 
fistula healing, the definition of which has often proved to be a contentious issue in fistula-in-
ano, many authors using follow-up which is too short or failing to use imaging to prove the 
absence of persistent occult tracts.  By contrast, Wilhelm used a combined clinical and 
radiological endpoint with a strict definition. A fistula was considered to have permanently 
healed if at 1 year all symptoms had completely disappeared, there was no evidence of 
recurrence (or persistence) on clinical, proctoscopic and endosonographic examination and 
there were no additional interventions required. A similar combined (but less stringent) 
clinical and radiological endpoint was recently used by Panes et al. in their study on stem 
cells in Crohn’s anal fistula [5]. The use of combined endpoints and longer follow-up is a 
welcome development in fistula surgery research.   
Interestingly, the authors used a further definition of success : primary success  if the fistula 
fulfilled the healing criteria after a single FiLaC intervention and secondary success if the 
healing occurred after a repeated post-FiLaC intervention. The primary and secondary 
success rates were 64.1% and 88%, respectively. The only variable which influenced 
success was intersphincteric versus transphincteric tracts based on the Parks classification. 
However, many of the comparisons tested included one much smaller group and are 
therefore at risk of type II error, including the question about the optimal method for closure 
of the internal opening . Whereas the length of the tract is thought to influence success with 
the fistula plug, the diameter of the tract may be important in FiLaC. The fixed penetration of 
the laser suggests that it may be less effective in the centre of a cavity, for example, or a 
wider section of tract. Magnetic resonance imaging (MRI) assessment of tract diameter prior 
to treatment may be an interesting variable for future analysis. 
The median follow- up duration of 25 months in Wilhelm’s study was sufficient to determine 
whether patients had recurred following FiLaC and clearly a secondary success rate of 88% 
is very promising. This is the longest follow-up of any series and although previous reports 
have shown high rates of success (9 out of 11 patients [6]; 41 of 50 patients [7]) the follow 
up has been limited to 12 months or less. The primary success rate, whilst not as 
impressive, mirrors that of many other sphincter preserving therapies such as advancement 
flaps and ligation of the intersphincteric fistula tract (LIFT). But the approach of combining 
more than one technique may actually be the most useful finding.  New techniques often 
combine several aspects which target different factors thought to lead to fistula persistence 
such as Video Assisted Anal Fistula Treatment (VAAFT) which, like FiLaC, uses an 
advancement flap technique to close the internal opening and disconnect the tract from the 
gut.  Tract preparation with preceding abscess drainage, laying open of secondary tracts, 
seton insertion and then curettage of the tract prior to the named procedure, are features of 
most studies of sphincter preserving procedures.  Further investigation into these aspects 
including use of a seton and the need to close the internal opening are worth undertaking in 
their own right.  
If one accepts the definition given by Wilhelm and colleagues, FiLaC is a credible option for 
patients who have failed previous treatments or have recurred in a short space of time. 
Given the higher success rate in intersphincteric fistulae, its use in simple fistulae may also 
be valuable, particularly in patients unwilling to countenance any risk of functional 
impairment.   
The question of ‘distalization’ of the fistula is an interesting one.  Many of the sphincter 
preserving techniques are said to be advantageous partly because failure does not preclude 
any other techniques or lead to harm.  The fistula plug may be an exception; some 
commentators have concluded that the openings are made larger by its presence when 
failure occurs.  Other techniques are said to lead to a more advantageous anatomy in failure.  
The recurrent fistula after failed LIFT may be intersphincteric, the transphincteric component 
having healed.  This may render the fistula more amenable to fistulotomy (or, given this 
report, to FiLaC).  If FiLaC does indeed lead to a reduction in the height of the fistula, this 
may also have an impact on feasibility of subsequent lay open, or of LIFT, which is easier in 
lower fistulae.  However, it is more difficult to hypothesise the mechanism for distalization 
than for the intersphincteric failure of the LIFT procedure; does the intersphincteric gland 
responsible for the fistula migrate?  The distalization claim requires further description and in 
particular, MRI confirmation of the old and new locations of the tract.   
Novel treatments must balance the risks of continence impairment and fistula recurrence. 
Specifically, surgeons (and patients) seek a genuinely sphincter preserving procedure with a 
success rate higher than 50-65%, which is a barrier that remains essentially unbroken.  
There have been few reports of episodes of major incontinence after FiLaC and the rare 
episodes of minor incontinence reported may well be related to concurrent pathology or 
previous sepsis/surgery. Another important consideration is that there was no significant 
difference  in patients with Crohn’s-related pathology and those whose fistulas were 
presumed to have a cryptoglandular aetiology although the Crohn’s group was too small for 
robust analysis. Certainly, the limited data so far suggest that FiLaC is an interesting and 
welcome addition to the surgeon’s armamentarium to treat complex fistulae.        
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